Rybelsus, which works like Novo’s Ozempic and Lilly’s Trulicity, gained FDA approval in 2019 as a daily oral alternative to those two drugs, which require weekly injections. However, that initial OK was accompanied by a recommendation doctors not prescribe Rybelsus as a first-line treatment for people with diabetes who are unable to control their blood sugar levels with diet and exercise alone. Merck’s Januvia and Lilly’s Jardiance, by comparison, already held approvals for that use.
“By taking Rybelsus first, people with Type 2 diabetes, in conjunction with their care teams, are now able to utilize this medicine early in their diabetes treatment journeys,” Aaron King, a family medicine and diabetes specialist in San Antonio, Texas said in a statement from Novo Nordisk.
Rybelsus has the same active ingredient as Ozempic, but at a higher dosage and modified to aid its absorption in the stomach.
The new use for Rybelsus comes as diabetes drug competition is intensifying. In the class of drugs called GLP-1 agonists, Rybelsus is the only oral treatment, but must be taken daily, while the latest injectable drugs can be taken once a week. READ MORE
By Jonathan Gardner
Source: biopharmadive.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
